Patents by Inventor Hyoun Rok Paik

Hyoun Rok Paik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • bacteriophage Clo-PEP-2 and use for inhibiting proliferation of same
    Patent number: 11529406
    Abstract: The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: December 20, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Hee Jeong Shin, Sang Hyeon Kang
  • bacteriophage pse-AEP-4 and use thereof for inhibiting proliferation of
    Patent number: 11497216
    Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-4 (accession number: KCTC 13166BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-4 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-4 as an active ingredient.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: November 15, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Hee Jeong Shin, Sang Hyeon Kang
  • Antibacterial protein EFAL-2 having bacteriolytic ability with respect to
    Patent number: 11492378
    Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP), which has the ability to kill Enterococcus faecium and an amino acid sequence represented by SEQ ID NO: 2, a pharmaceutical composition containing the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium using the pharmaceutical composition.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: November 8, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang
  • bacteriophage Pse-AEP-3 and use thereof for inhibiting proliferation of
    Patent number: 11457635
    Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-3 (accession number: KCTC 13165BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-3 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-3 as an active ingredient.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: October 4, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Hee Jeong Shin, Sang Hyeon Kang
  • bacteriophage Ent-FAP-4 and use for inhibiting proliferation of same
    Patent number: 11458177
    Abstract: The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by administering the pharmaceutical composition.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: October 4, 2022
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Sang Hyeon Kang
  • bacteriophage Esc-COP-7, and use thereof for suppressing proliferation of pathogenic
    Patent number: 11412760
    Abstract: The present invention relates to a Myoviridae bacteriophage ESC-COP-7 (accession number KCTC 13130BP) isolated from nature, and a method for preventing and treating infections from pathogenic Escherichia coli by means of a composition containing the Myoviridae bacteriophage ESC-COP-7 as an active ingredient, the Myoviridae bacteriophage ESC-COP-7 being characterized by having the capability to specifically kill Escherichia coli, and genome expressed by the SEQ ID 1.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: August 16, 2022
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, SAng Hyeon Kang
  • bacteriophage Esc-COP-9 and use for inhibiting proliferation of pathogenic thereof
    Patent number: 11213050
    Abstract: The present invention relates to a Siphoviridae bacteriophage Esc-COP-9 (Accession number: KCTC 13131BP) isolated from nature, which has the ability to specifically kill Escherichia coli and which includes a genome expressed by SEQ. ID. NO: 1, and to a method of preventing and treating a pathogenic Escherichia coli infection using a composition including the same as an active ingredient.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 4, 2022
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Sang Hyeon Kang
  • NOVEL ANTIBACTERIAL PROTEIN EFAL-2 HAVING BACTERIOLYTIC ABILITY WITH RESPECT TO ENTEROCOCCUS FAECIUM
    Publication number: 20210070809
    Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP), which has the ability to kill Enterococcus faecium and an amino acid sequence represented by SEQ ID NO: 2, a pharmaceutical composition containing the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium using the pharmaceutical composition.
    Type: Application
    Filed: November 20, 2020
    Publication date: March 11, 2021
    Inventors: Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang
  • NOVEL SALMONELLA TYPHIMURIUM BACTERIOPHAGE STP-2 AND USE THEREOF FOR INHIBITING PROLIFERATION OF SALMONELLA TYPHIMURIUM
    Publication number: 20210054345
    Abstract: The present invention relates to a Siphoviridae bacteriophage STP-2 (Accession number: KCTC 12853BP) isolated from nature and characterized by having the ability to destroy Salmonella Typhimurium and having a genome represented by SEQ ID NO:1; and to a method for preventing and treating diseases caused by Salmonella Typhimurium using Siphoviridae bacteriophage STP-2 containing the same as an active ingredient.
    Type: Application
    Filed: February 19, 2019
    Publication date: February 25, 2021
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Beom Seok Kim, Sang Hyeon Kang
  • bacteriophage Bor-BRP-1, and use thereof for inhibition of proliferation of bacteria
    Patent number: 10894068
    Abstract: The present invention relates to a Podoviridae bacteriophage Bor-BRP-1 (accession no. KCTC 12705BP) isolated from nature, which has an ability to specifically kill Bordetella bronchiseptica bacteria and has a genome represented by SEQ ID NO: 1; and a method for preventing and treating infection with Bordetella bronchiseptica bacteria using a composition comprising the same as an active ingredient.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: January 19, 2021
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim, Sang Hyeon Kang
  • bacteriophage Pas-MUP-1 and use thereof for inhibiting proliferation of
    Patent number: 10568917
    Abstract: The present invention relates to: Myoviridae bacteriophage Pas-MUP-1 (accession number KCTC 12706BP) which has the capability to specifically destroy Pasteurella multocida, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Pasteurella multocida infections, using a composition containing bacteriophage Pas-MUP-1 as an active ingredient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 25, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Dong Min Kang, Sang Hyeon Kang
  • NOVEL CLOSTRIDIUM PERFRINGENS BACTERIOPHAGE CLO-PEP-2 AND USE FOR INHIBITING CLOSTRIDIUM PERFRINGENS PROLIFERATION OF SAME
    Publication number: 20200054042
    Abstract: The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.
    Type: Application
    Filed: January 11, 2018
    Publication date: February 20, 2020
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Hee Jeong Shin, Sang Hyeon Kang
  • NOVEL ANTIBACTERIAL PROTEIN EFAL-2 HAVING BACTERIOLYTIC ABILITY WITH RESPECT TO ENTEROCOCCUS FAECIUM
    Publication number: 20200055902
    Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (deposition number KCTC 12854BP), a pharmaceutical composition including the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium by using the pharmaceutical composition, the antibacterial protein EFAL-2 being characterized by having the ability capable of killing Enterococcus faecium and having an amino acid sequence represented by SEQ ID NO: 2.
    Type: Application
    Filed: January 11, 2018
    Publication date: February 20, 2020
    Inventors: Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang
  • NOVEL ENTEROCOCCUS FAECIUM BACTERIOPHAGE ENT-FAP-4 AND USE FOR INHIBITING ENTEROCOCCUS FAECIUM PROLIFERATION OF SAME
    Publication number: 20200054700
    Abstract: The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by means of the pharmaceutical composition.
    Type: Application
    Filed: January 11, 2018
    Publication date: February 20, 2020
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Sang Hyeon Kang
  • NOVEL PSEUDOMONAS AERUGINOSA BACTERIOPHAGE PSE-AEP-3 AND USE THEREOF FOR INHIBITING PROLIFERATION OF PSEUDOMONAS AERUGINOSA
    Publication number: 20190359948
    Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-3 (accession number: KCTC 13165BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-3 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-3 as an active ingredient.
    Type: Application
    Filed: January 11, 2018
    Publication date: November 28, 2019
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Hee Jeong Shin, Sang Hyeon Kang
  • NOVEL PSEUDOMONAS AERUGINOSA BACTERIOPHAGE PSE-AEP-4 AND USE THEREOF FOR INHIBITING PROLIFERATION OF PSEUDOMONAS AERUGINOSA
    Publication number: 20190359949
    Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-4 (accession number: KCTC 13166BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-4 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-4 as an active ingredient.
    Type: Application
    Filed: January 11, 2018
    Publication date: November 28, 2019
    Inventors: Seong Jun Yoon, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Hee Jeong Shin, Sang Hyeon Kang
  • ESCHERICHIA COLI BACTERIOPHAGE ESC-COP-7, AND USE THEREOF FOR SUPPRESSING PROLIFERATION OF PATHOGENIC ESCHERICHIA COLI
    Publication number: 20190321424
    Abstract: The present invention relates to a Myoviridae bacteriophage ESC-COP-7 (accession number KCTC 13130BP) isolated from nature, and a method for preventing and treating infections from pathogenic Escherichia coli by means of a composition containing the Myoviridae bacteriophage ESC-COP-7 as an active ingredient, the Myoviridae bacteriophage ESC-COP-7 being characterized by having the capability to specifically kill Escherichia coli, and genome expressed by the SEQ ID 1.
    Type: Application
    Filed: September 29, 2017
    Publication date: October 24, 2019
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, SAng Hyeon Kang
  • ESCHERICHIA COLI BACTERIOPHAGE ESC-COP-9 AND USE FOR INHIBITING PROLIFERATION OF PATHOGENIC ESCHERICHIA COLI THEREOF
    Publication number: 20190321423
    Abstract: The present invention relates to Myoviridae bacteriophage Esc-COP-9 (Accession No. KCTC 13131BP) isolated from nature, which has a genome represented by SEQ ID NO: 1 and an ability to specifically kill E.coli, and a method for preventing and treating pathogenic E. coli infections by using a composition comprising the same as an active ingredient.
    Type: Application
    Filed: September 29, 2017
    Publication date: October 24, 2019
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Sang Hyeon Kang
  • NOVEL BORDETELLA BRONCHISEPTICA BACTERIOPHAGE BOR-BRP-1, AND USE THEREOF FOR INHIBITION OF PROLIFERATION OF BORDETELLA BRONCHISEPTICA BACTERIA
    Publication number: 20190231831
    Abstract: The present invention relates to a Podoviridae bacteriophage Bor-BRP-1 (accession no. KCTC 12705BP) isolated from nature, which has an ability to specifically kill Bordetella bronchiseptica bacteria and has a genome represented by SEQ ID NO: 1; and a method for preventing and treating infection with Bordetella bronchiseptica bacteria using a composition comprising the same as an active ingredient.
    Type: Application
    Filed: June 13, 2017
    Publication date: August 1, 2019
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim, Sang Hyeon Kang
  • Enterohemorrhagic bacteriophage Esc-CHP-1 and use thereof for inhibiting proliferation of enterohemorrhagic
    Patent number: 10265353
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-CHP-1 that is isolated from the nature and can kill specifically enterohemorrhagic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12660BP), and a method for preventing and treating the infections of enterohemorrhagic E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin